Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Symposium to discuss latest scientific and clinical advances in treating non-Hodgkins lymphoma

Fifty world-renowned experts in non-Hodgkins lymphoma will convene in New York in November to present the latest scientific and clinical advances in treating a "lost generation" of sufferers-children, young adults and adolescents.

31 Oct 2012

Night work can increase risk of cancer in men

Night work can increase cancer risk in men, according to a new study published in the American Journal of Epidemiology by a research team from Centre INRS-Institut Armand-Frappier and Centre de recherche du Centre hospitalier de l'Universit- de Montr-al.

16 Oct 2012

University of Iowa, Mayo Clinic to continue SPORE for lymphoma research

The Mayo Clinic Cancer Center and Holden Comprehensive Cancer Center at the University of Iowa have received a five-year, $11.5 million grant renewal from the National Cancer Institute (NCI) to continue the Specialized Program of Research Excellence (SPORE) for lymphoma research.

25 Sep 2012

$Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma$

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

Cell Therapeutics, Inc. announced today that the phase 1 study data of its highly selective oral JAK2 inhibitor pacritinib, or SB1518, showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed/refractory lymphoma.

24 Sep 2012

Biovest seeks EMA approval for BiovaxID to treat non-Hodgkin's lymphoma

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today reported milestone achievements advancing BiovaxID, Biovest's personalized cancer vaccine for the treatment of non-Hodgkin's lymphoma, including a recently conducted regulatory meeting with the European Medicines Agency (EMA) and the appointment of a key contributor to the Human Genome Project to its Scientific Advisory Board.

21 Sep 2012

Cell Therapeutics launches Pixuvri in the European Union

Cell Therapeutics, Inc., a company focused on translating science into novel cancer therapies, today announced the initiation of the commercial launch of Pixuvri in the European Union with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, United Kingdom and the Netherlands in November 2012.

11 Sep 2012

Longer looks: Insurers balk at price of new asthma relief; Despite health law, costs still overwhelming for some patients

For two decades, Patricia DiGiusto struggled with severe asthma. Powerful medications and frequent use of her inhaler could not prevent repeated trips to the emergency room. ... Two years ago, Ms. DiGiusto's doctor told her about a new procedure called bronchial thermoplasty, the first non-drug therapy approved by the Food and Drug Administration for patients with severe asthma.

7 Sep 2012

Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

The U.S. Food and Drug Administration today approved Sicor Biotech's tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.

30 Aug 2012

Radiation therapy alone no longer the best choice for early follicular lymphoma

A University of Rochester Medical Center study published in the Journal of Clinical Oncology, challenges treatment guidelines for early stage follicular lymphoma, concluding that six different therapies can bring a remission, particularly if the patient is carefully examined and staged at diagnosis.

22 Aug 2012

FDA requests Biovest to conduct second Phase III trial of BV301 for NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that it conducted a formal clinical guidance meeting with the U.S. FDA to determine the most expeditious U.S. registration pathway for BiovaxID, its personalized cancer vaccine for the consolidation treatment of follicular non-Hodgkin's lymphoma.

15 Aug 2012

Biovest receives Rapporteur and Co-Rapporteur designation for BiovaxID personalized cancer vaccine

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has notified Biovest regarding the official designation of the Rapporteur and Co-Rapporteur for BiovaxID, a personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma.

30 Jul 2012

Karyopharm commences two KPT-330 phase 1 studies in cancers

Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced dosing of patients in the first-in-human clinical trials with KPT-330.

25 Jul 2012

Biokine receives FDA Orphan Drug designation for BKT140 to treat hematological cancers

Biokine Therapeutics Ltd. announced today that it has received Orphan Drug designation from the US Food and Drug Administration (FDA) for the mobilization of hematopoietic stem cells from bone marrow into peripheral blood for collection and subsequent transplantation in patients with hematological cancers.

24 Jul 2012

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

Millennium: The Takeda Oncology Company and, Takeda Pharmaceutical Company Limited today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for conditional approval of brentuximab vedotin for two indications.

21 Jul 2012

Bryologs more potent than prostratin in treating HIV

Thanks to antiretrovirals, an AIDS diagnosis hasn't been a death sentence for nearly two decades. But highly active antiretroviral therapy, or HAART, is also not a cure.

19 Jul 2012

Inhibiting STAT3 might unleash an effective anti-lymphoma immune response

Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.

19 Jul 2012

‘Open to Options’ guides cancer patients in making critical health decisions

Cancer patients across the country have a new way to navigate through difficult treatment decisions and communicate better with their doctors. "Open to Options," which recently launched nationally, was developed in conjunction with UCSF to guide patients in making critical health decisions.

11 Jul 2012

Connections between daily stressors of police work and obesity, suicide

The daily psychological stresses that police officers experience in their work put them at significantly higher risk than the general population for a host of long-term physical and mental health effects. That's the overall finding of a major scientific study of the Buffalo Police Department called Buffalo Cardio-Metabolic Occupational Police Stress (BCOPS) conducted over five years by a University at Buffalo researcher.

11 Jul 2012

Radiotherapy redundant in low-risk Hodgkin lymphoma treatment

Children with low-risk Hodgkin lymphoma who respond well to chemotherapy may not require additional radiotherapy, suggest study results.

10 Jul 2012

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options.

28 Jun 2012

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Symposium to discuss latest scientific and clinical advances in treating non-Hodgkins lymphoma

Night work can increase risk of cancer in men

University of Iowa, Mayo Clinic to continue SPORE for lymphoma research

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

Biovest seeks EMA approval for BiovaxID to treat non-Hodgkin's lymphoma

Cell Therapeutics launches Pixuvri in the European Union

Longer looks: Insurers balk at price of new asthma relief; Despite health law, costs still overwhelming for some patients

Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

Radiation therapy alone no longer the best choice for early follicular lymphoma

FDA requests Biovest to conduct second Phase III trial of BV301 for NHL

Biovest receives Rapporteur and Co-Rapporteur designation for BiovaxID personalized cancer vaccine

Karyopharm commences two KPT-330 phase 1 studies in cancers

Biokine receives FDA Orphan Drug designation for BKT140 to treat hematological cancers

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

Bryologs more potent than prostratin in treating HIV

Inhibiting STAT3 might unleash an effective anti-lymphoma immune response

‘Open to Options’ guides cancer patients in making critical health decisions

Connections between daily stressors of police work and obesity, suicide

Radiotherapy redundant in low-risk Hodgkin lymphoma treatment

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in